[{"address1": "18702 N. Creek Parkway", "address2": "Suite 100", "city": "Bothell", "state": "WA", "zip": "98011", "country": "United States", "phone": "610 321 3700", "website": "https://immunome.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.", "fullTimeEmployees": 105, "companyOfficers": [{"maxAge": 1, "name": "Dr. Clay B. Siegall Ph.D.", "age": 63, "title": "President, CEO & Chairman", "yearBorn": 1961, "fiscalYear": 2023, "totalPay": 1433088, "exercisedValue": 0, "unexercisedValue": 12996163}, {"maxAge": 1, "name": "Dr. Jack  Higgins Ph.D.", "age": 44, "title": "Chief Scientific Officer", "yearBorn": 1980, "fiscalYear": 2023, "totalPay": 956342, "exercisedValue": 0, "unexercisedValue": 734891}, {"maxAge": 1, "name": "Dr. Robert J. Lechleider M.D.", "age": 63, "title": "Chief Medical Officer", "yearBorn": 1961, "fiscalYear": 2023, "totalPay": 512488, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Max  Rosett", "age": 34, "title": "Executive VP of Operations, Principal Accounting & Financial Officer and CFO", "yearBorn": 1990, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Philip  Tsai", "title": "Chief Technical Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Sandra G. Stoneman Esq., J.D.", "age": 51, "title": "Chief Legal Officer, General Counsel & Corporate Secretary", "yearBorn": 1973, "fiscalYear": 2023, "totalPay": 443432, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Bruce  Turner M.D., Ph.D.", "age": 60, "title": "Chief Strategy Officer", "yearBorn": 1964, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Kinney  Horn", "age": 49, "title": "Chief Business Officer", "yearBorn": 1975, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Roee  Shahar", "title": "Executive Vice President of Commercial", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 9, "compensationRisk": 10, "shareHolderRightsRisk": 7, "overallRisk": 10, "governanceEpochDate": 1738368000, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 10.43, "open": 10.46, "dayLow": 10.175, "dayHigh": 10.6, "regularMarketPreviousClose": 10.43, "regularMarketOpen": 10.46, "regularMarketDayLow": 10.175, "regularMarketDayHigh": 10.6, "beta": 1.904, "forwardPE": -3.9694657, "volume": 359567, "regularMarketVolume": 359567, "averageVolume": 991964, "averageVolume10days": 1339330, "averageDailyVolume10Day": 1339330, "bid": 10.38, "ask": 10.47, "bidSize": 100, "askSize": 100, "marketCap": 880618880, "fiftyTwoWeekLow": 8.97, "fiftyTwoWeekHigh": 30.958, "priceToSalesTrailing12Months": 86.94036, "fiftyDayAverage": 11.2096, "twoHundredDayAverage": 13.016025, "currency": "USD", "enterpriseValue": 411726176, "floatShares": 47438675, "sharesOutstanding": 84674896, "sharesShort": 9069818, "sharesShortPriorMonth": 9873217, "sharesShortPreviousMonthDate": 1735603200, "dateShortInterest": 1738281600, "sharesPercentSharesOut": 0.1071, "heldPercentInsiders": 0.19304001, "heldPercentInstitutions": 0.62911, "shortRatio": 9.1, "shortPercentOfFloat": 0.1114, "impliedSharesOutstanding": 84674896, "bookValue": 3.557, "priceToBook": 2.9238122, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -305348000, "trailingEps": -7.94, "forwardEps": -2.9, "enterpriseToRevenue": 40.648, "enterpriseToEbitda": -3.728, "52WeekChange": -0.5465218, "SandP52WeekChange": 0.22903383, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "IMNM", "underlyingSymbol": "IMNM", "shortName": "Immunome, Inc.", "longName": "Immunome, Inc.", "firstTradeDateEpochUtc": 1601645400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "c2147e86-3bc9-3a00-bf6a-53fc4499717d", "messageBoardId": "finmb_108518404", "gmtOffSetMilliseconds": -18000000, "currentPrice": 10.4, "targetHighPrice": 38.0, "targetLowPrice": 21.0, "targetMeanPrice": 30.0, "targetMedianPrice": 31.5, "recommendationMean": 1.28571, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 6, "totalCash": 240130000, "totalCashPerShare": 3.847, "ebitda": -110441000, "totalDebt": 2721000, "quickRatio": 6.075, "currentRatio": 6.174, "totalRevenue": 10129000, "debtToEquity": 1.266, "revenuePerShare": 0.189, "returnOnAssets": -0.39889, "returnOnEquity": -2.7635598, "grossProfits": -80996000, "freeCashflow": -94124128, "operatingCashflow": -86193000, "revenueGrowth": -0.184, "operatingMargins": -15.05704, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-02-15"}]